Developer docs
API playgroundTry for free, no card

Search company profiles

Galux

Full company profile

uuid0000tgb

Namestring
Galux
Legal namestring
Galux Inc. (갤럭스 주식회사)
Websiteurl
galux.co.kr
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Galux Inc. (갤럭스 주식회사) is a South Korean privately held biotechnology company founded in 2020, headquartered in Seoul with an R&D wet-lab center in Gangseo-gu. The company develops AI-driven protein therapeutics design technology centered on its proprietary platform GaluxDesign, which integrates artificial intelligence with physics-based first principles to enable modality-agnostic de novo design of therapeutic proteins, with demonstrated strength in de novo antibody design.

The GaluxDesign platform has been validated through peer-reviewed publications in Science Advances (T-SCAPE immunogenicity scoring co-developed with Seoul National University) and bioRxiv, and demonstrated the broadest target coverage in a comparative de novo antibody design study, achieving experimentally validated binders for 8 of 9 publicly comparable targets. The company has extended platform capabilities to challenging target classes including GPCRs and ion channels, with reported high consistency between AI-designed antibodies and cryo-EM experimental structures.

Galux operates as a B2B biotech through a partnership-driven go-to-market model, generating revenue via co-development agreements, research partnerships, and platform services with global and regional pharmaceutical companies. Named partners include Boehringer Ingelheim, Celltrion, LG Chem, HanAll Biopharma, Y-Biologics, GC Biopharma, AimedBio, OliX, ISU Abxis, and Woojung Bio, spanning cancer, autoimmune, rare disease, siRNA delivery, and blood-brain barrier-crossing therapeutic programs. The company is venture-backed with $47 million raised across a 2021 strategic round (Kakao Brain), 2022 Series A, and February 2026 Series B led by InterVest and DAYLI Partners, with 11-50 employees and revenue figures undisclosed.

Short descriptiontext

Galux is a South Korean biotech company developing the AI-native GaluxDesign platform for de novo protein and antibody therapeutics design, serving global pharmaceutical companies through co-development partnerships and platform services targeting cancer, autoimmune, and rare diseases.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersDogokdong, South Korea
HQ citystring
Dogokdong
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI protein design, antibody therapeutics, drug discovery platform, de novo protein engineering, computational biology
Industry2 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Software Publishers513210
SIC code1 code
  • Services-Prepackaged Software7372
Product category
AI Drug Discovery / Computational Protein Design
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Co-development and Research Partnerships
TypeLicensing Royalties
Description

Galux generates revenue through strategic co-development agreements with pharmaceutical companies. These partnerships involve joint research agreements where Galux provides AI-driven protein design capabilities while partners contribute to preclinical/clinical development, funding, and commercialization. Examples include collaborations with Boehringer Ingelheim, Celltrion, LG Chem, and others.

galux.co.kr
2AI Platform Licensing and Services
TypeProfessional Services
Description

Revenue generated from licensing GaluxDesign platform technology and providing AI protein design services to pharmaceutical partners for specific therapeutic programs.

biospace.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1GaluxDesign
Description

Galux's proprietary AI platform for de novo protein design that integrates artificial intelligence and physical principles for antibody and protein therapeutics design.

galux.co.kr
Core offering1 text field

Galux develops and operates GaluxDesign, a proprietary AI platform that integrates artificial intelligence with physics-based principles to design therapeutic proteins from scratch (de novo protein design). The platform is modality-agnostic and is delivered to pharmaceutical partners through co-development agreements, joint research collaborations, and licensing arrangements to accelerate discovery of antibody therapeutics for autoimmune diseases, cancer, and rare/incurable diseases.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Achieved broadest target coverage in de novo antibody design - 8 out of 9 targets validated vs competitors' lower success rates
+3 more records
Product overview1 text field

Galux develops AI-driven protein therapeutics design as a single unified offering centered on its GaluxDesign platform. This proprietary AI platform integrates artificial intelligence with physics-based first principles to enable de novo design of therapeutic proteins, particularly antibodies. The platform is modality-agnostic and supports design across challenging target classes including GPCRs and ion channels. Galux also offers T-SCAPE, a complementary T cell immunogenicity scoring tool developed with Seoul National University, which provides safety assessment for designed therapeutics. The company operates through research collaborations and partnerships with pharmaceutical companies, providing access to its platform capabilities for joint drug development programs rather than licensing the software as a standalone product.

Product and service2 records
1GaluxDesign
CategoryAI Drug Discovery Platform
Description

Proprietary AI platform that integrates artificial intelligence with physics-based first principles to design therapeutic proteins from scratch (de novo design). The platform is modality-agnostic and has demonstrated unprecedented accuracy in de novo antibody design, including challenging target classes such as GPCRs and ion channels. Delivered to pharmaceutical partners through co-development agreements and joint research collaborations.

2T-SCAPE
CategoryAI Drug Safety Assessment
Description

T-SCAPE (T cell immunogenicity scoring via cross-domain aided predictive engine) is an AI tool developed in collaboration with Seoul National University for predicting and scoring the immunogenicity of drug candidates, supporting safety assessment of designed therapeutics.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-01
Description

Investment and joint research agreement to develop a blood-brain barrier-crossing protein delivery platform combining Galux's AI-based protein design with antibody drug development with AimedBio's expanding ADC development capabilities. The partnership aims to address a major technical hurdle in brain disease treatment.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-01
Description

Galux partnered with GC Biopharma to develop antibody therapeutics for autoimmune diseases using Galux's AI platform for de novo antibody design and GC Biopharma's R&D capabilities in oncology, immunology, and rare diseases. Galux designs and optimizes AI-generated antibody candidates while GC Biopharma conducts experimental validation.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-01
Description

Partnership for AI-based siRNA delivery platform development combining Galux's protein design AI with OliX's siRNA delivery technology.

4Boehringer Ingelheim
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-12-01
Description

Galux signed a joint research agreement with Boehringer Ingelheim to evaluate whether Galux's AI platform can consistently design functional proteins from scratch using the GaluxDesign platform. The collaboration tests whether the system can produce proteins difficult to generate through conventional discovery methods by encoding functional requirements directly into the design process. Financial terms and specific therapeutic targets were not disclosed.

genengnews.com
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-12-01
Description

Korean biopharma company Celltrion partnered with Galux to develop multispecific antibody drugs for autoimmune diseases. Galux focuses on AI-based antibody design while Celltrion handles preclinical and clinical development, aiming to accelerate drug development and improve success rates.

6ISU Abxis
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-11-01
Description

Collaboration to develop next-generation therapies for rare diseases using Galux's AI-driven drug discovery capabilities.

galux.co.kr
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-01
Description

AI-based immune anticancer treatment co-development partnership combining Galux's protein design AI with Y-Biologics' expertise.

8Woojung Bio
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-01
Description

Strategic partnership to accelerate AI-driven therapeutics development combining both companies' capabilities.

galux.co.kr
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-06-01
Description

Strategic collaboration to develop AI-designed antibody therapeutics for cancer using Galux's de novo antibody design capabilities.

10LG Chem
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Joint drug development programs for cancer therapeutics using Galux's AI-driven protein design platform.

techstartups.com
11Seoul National University
Strategic tierCoreTypeOthers
Description

Co-development of T-SCAPE, an AI for predicting immunogenicity of drug candidates, combining academic research capabilities with industry application.

galux.co.kr
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US-based AI biotech developing JAM-2 for de novo antibody and protein design. Most directly comparable peer — Galux's May 2026 comparative benchmark explicitly measured GaluxDesign against Nabla Bio's JAM-2 on the same 9 publicly known targets.

TypeDirect peer
Description

AI-driven protein design company behind the Chai-2 platform. Named alongside JAM-2 as a direct head-to-head competitor in Galux's May 2026 comparative study; competes for the same pharma co-development deals in de novo antibody design.

TypeDirect peer
Description

US-based generative biology company founded by Flagship Pioneering building a platform for de novo protein therapeutics design. Direct competitor in AI-driven antibody and protein design with major pharma partnerships.

4Isomorphic Labs
TypeBroad incumbent
Description

Alphabet-owned AI drug discovery company applying DeepMind's AlphaFold to drug design. Operates at much larger scale than Galux with major pharma partnerships (Eli Lilly, Novartis) and represents the most capitalized competitor in AI protein design.

TypeBroad incumbent
Description

Canadian public antibody discovery platform company with established pharma partnerships. Comparable as a horizontal antibody-discovery platform, though its technology stack emphasizes high-throughput wet-lab screening rather than pure de novo AI design.

TypeBroad incumbent
Description

Hong Kong-headquartered AI drug discovery company with Pharma.AI platform covering target discovery, generative chemistry, and clinical trial prediction. Broader scope than Galux but competing for the same AI-driven drug discovery budget pool at major pharma.

TypeDirect peer
Description

AI-driven drug discovery company (formerly Entos) building physics-informed ML platforms for de novo antibody and small-molecule design. Closely comparable in technical approach (physics + AI) and stage, with pharma partnerships.

TypeDirect peer
Description

US-based AI protein design company founded by Salesforce researchers, focused on de novo functional protein generation using large language models. Direct competitor in AI-driven protein engineering for therapeutics.

TypeEmerging player
Description

Early-stage AI protein foundation model company founded by former Meta AI researchers. Emerging competitor with frontier-scale models for protein design; overlap with GaluxDesign's generative AI capability.

TypeEmerging player
Description

Amsterdam-based AI protein engineering company with platform for designing antibodies, enzymes, and other proteins. Comparable as a generative biology platform though currently focused more on industrial biotech applications than pure therapeutics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers11 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Galux

AI Drug Discovery / Computational Protein Designgalux.co.kr

Galux is a South Korean biotech company developing the AI-native GaluxDesign platform for de novo protein and antibody therapeutics design, serving global pharmaceutical companies through co-development partnerships and platform services targeting cancer, autoimmune, and rare diseases.

What Galux does

Galux Inc. (갤럭스 주식회사) is a South Korean privately held biotechnology company founded in 2020, headquartered in Seoul with an R&D wet-lab center in Gangseo-gu. The company develops AI-driven protein therapeutics design technology centered on its proprietary platform GaluxDesign, which integrates artificial intelligence with physics-based first principles to enable modality-agnostic de novo design of therapeutic proteins, with demonstrated strength in de novo antibody design.

The GaluxDesign platform has been validated through peer-reviewed publications in Science Advances (T-SCAPE immunogenicity scoring co-developed with Seoul National University) and bioRxiv, and demonstrated the broadest target coverage in a comparative de novo antibody design study, achieving experimentally validated binders for 8 of 9 publicly comparable targets. The company has extended platform capabilities to challenging target classes including GPCRs and ion channels, with reported high consistency between AI-designed antibodies and cryo-EM experimental structures.

Galux operates as a B2B biotech through a partnership-driven go-to-market model, generating revenue via co-development agreements, research partnerships, and platform services with global and regional pharmaceutical companies. Named partners include Boehringer Ingelheim, Celltrion, LG Chem, HanAll Biopharma, Y-Biologics, GC Biopharma, AimedBio, OliX, ISU Abxis, and Woojung Bio, spanning cancer, autoimmune, rare disease, siRNA delivery, and blood-brain barrier-crossing therapeutic programs. The company is venture-backed with $47 million raised across a 2021 strategic round (Kakao Brain), 2022 Series A, and February 2026 Series B led by InterVest and DAYLI Partners, with 11-50 employees and revenue figures undisclosed.

Galux firmographics

Firmographics
Name
Galux
Legal name
Galux Inc. (갤럭스 주식회사)
Website
https://galux.co.kr
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Galux is a South Korean biotech company developing the AI-native GaluxDesign platform for de novo protein and antibody therapeutics design, serving global pharmaceutical companies through co-development partnerships and platform services targeting cancer, autoimmune, and rare diseases.
Ownership category
akta.pro rank

Galux industry classification

Industry
Product category
AI Drug Discovery / Computational Protein Design
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Software Publishers (513210)
SIC
Services-Prepackaged Software (7372)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • AI protein design
  • Antibody therapeutics
  • Drug discovery platform
  • De novo protein engineering
  • Computational biology

Where Galux is headquartered

Location

Headquarters

HQ city
Dogokdong
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

Galux business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Co-development and Research Partnerships: Galux generates revenue through strategic co-development agreements with pharmaceutical companies. These partnerships involve joint research agreements where Galux provides AI-driven protein design capabilities while partners contribute to preclinical/clinical development, funding, and commercialization. Examples include collaborations with Boehringer Ingelheim, Celltrion, LG Chem, and others.
  2. AI Platform Licensing and Services: Revenue generated from licensing GaluxDesign platform technology and providing AI protein design services to pharmaceutical partners for specific therapeutic programs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Galux product offering

Product offering

Core offering

Galux develops and operates GaluxDesign, a proprietary AI platform that integrates artificial intelligence with physics-based principles to design therapeutic proteins from scratch (de novo protein design). The platform is modality-agnostic and is delivered to pharmaceutical partners through co-development agreements, joint research collaborations, and licensing arrangements to accelerate discovery of antibody therapeutics for autoimmune diseases, cancer, and rare/incurable diseases.

Product overview

Galux develops AI-driven protein therapeutics design as a single unified offering centered on its GaluxDesign platform. This proprietary AI platform integrates artificial intelligence with physics-based first principles to enable de novo design of therapeutic proteins, particularly antibodies. The platform is modality-agnostic and supports design across challenging target classes including GPCRs and ion channels. Galux also offers T-SCAPE, a complementary T cell immunogenicity scoring tool developed with Seoul National University, which provides safety assessment for designed therapeutics. The company operates through research collaborations and partnerships with pharmaceutical companies, providing access to its platform capabilities for joint drug development programs rather than licensing the software as a standalone product.

Differentiator

Problem solved

Functional benefit

Brands

  • GaluxDesign: Galux's proprietary AI platform for de novo protein design that integrates artificial intelligence and physical principles for antibody and protein therapeutics design.

Products and services

  • GaluxDesign Proprietary AI platform that integrates artificial intelligence with physics-based first principles to design therapeutic proteins from scratch (de novo design). The platform is modality-agnostic and has demonstrated unprecedented accuracy in de novo antibody design, including challenging target classes such as GPCRs and ion channels. Delivered to pharmaceutical partners through co-development agreements and joint research collaborations.
  • T-SCAPE T-SCAPE (T cell immunogenicity scoring via cross-domain aided predictive engine) is an AI tool developed in collaboration with Seoul National University for predicting and scoring the immunogenicity of drug candidates, supporting safety assessment of designed therapeutics.

Quantifiable outcome

  • Achieved broadest target coverage in de novo antibody design - 8 out of 9 targets validated vs competitors' lower success rates
  • +3 more outcomes

Companies that use Galux

Customer profile

Named customers11 records

Segments2 records

Ideal customer profiles1 record

Galux technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Galux partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core and flagship.

  • AimedBiocoreStrategic or Co-development Partner · 1 May 2026Investment and joint research agreement to develop a blood-brain barrier-crossing protein delivery platform combining Galux's AI-based protein design with antibody drug development with AimedBio's expanding ADC development capabilities. The partnership aims to address a major technical hurdle in brain disease treatment.
  • GC BiopharmacoreStrategic or Co-development Partner · 1 April 2026Galux partnered with GC Biopharma to develop antibody therapeutics for autoimmune diseases using Galux's AI platform for de novo antibody design and GC Biopharma's R&D capabilities in oncology, immunology, and rare diseases. Galux designs and optimizes AI-generated antibody candidates while GC Biopharma conducts experimental validation.
  • OliXcoreStrategic or Co-development Partner · 1 April 2026Partnership for AI-based siRNA delivery platform development combining Galux's protein design AI with OliX's siRNA delivery technology.
  • Boehringer IngelheimflagshipStrategic or Co-development Partner · 1 December 2025Galux signed a joint research agreement with Boehringer Ingelheim to evaluate whether Galux's AI platform can consistently design functional proteins from scratch using the GaluxDesign platform. The collaboration tests whether the system can produce proteins difficult to generate through conventional discovery methods by encoding functional requirements directly into the design process. Financial terms and specific therapeutic targets were not disclosed.
  • CelltrionflagshipStrategic or Co-development Partner · 1 December 2025Korean biopharma company Celltrion partnered with Galux to develop multispecific antibody drugs for autoimmune diseases. Galux focuses on AI-based antibody design while Celltrion handles preclinical and clinical development, aiming to accelerate drug development and improve success rates.
  • ISU AbxiscoreStrategic or Co-development Partner · 1 November 2025Collaboration to develop next-generation therapies for rare diseases using Galux's AI-driven drug discovery capabilities.
  • Y-BiologicscoreStrategic or Co-development Partner · 1 September 2025AI-based immune anticancer treatment co-development partnership combining Galux's protein design AI with Y-Biologics' expertise.
  • Woojung BiocoreStrategic or Co-development Partner · 1 September 2025Strategic partnership to accelerate AI-driven therapeutics development combining both companies' capabilities.
  • HanAll BiopharmacoreStrategic or Co-development Partner · 1 June 2025Strategic collaboration to develop AI-designed antibody therapeutics for cancer using Galux's de novo antibody design capabilities.
  • LG ChemcoreStrategic or Co-development PartnerJoint drug development programs for cancer therapeutics using Galux's AI-driven protein design platform.
  • Seoul National UniversitycoreOthersCo-development of T-SCAPE, an AI for predicting immunogenicity of drug candidates, combining academic research capabilities with industry application.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Galux competitors and assessment

Company assessment

Direct peers

  • Nabla Bio: US-based AI biotech developing JAM-2 for de novo antibody and protein design. Most directly comparable peer — Galux's May 2026 comparative benchmark explicitly measured GaluxDesign against Nabla Bio's JAM-2 on the same 9 publicly known targets.
  • Chai Discovery: AI-driven protein design company behind the Chai-2 platform. Named alongside JAM-2 as a direct head-to-head competitor in Galux's May 2026 comparative study; competes for the same pharma co-development deals in de novo antibody design.
  • Generate Biomedicines: US-based generative biology company founded by Flagship Pioneering building a platform for de novo protein therapeutics design. Direct competitor in AI-driven antibody and protein design with major pharma partnerships.
  • Iambic Therapeutics: AI-driven drug discovery company (formerly Entos) building physics-informed ML platforms for de novo antibody and small-molecule design. Closely comparable in technical approach (physics + AI) and stage, with pharma partnerships.
  • Profluent Bio: US-based AI protein design company founded by Salesforce researchers, focused on de novo functional protein generation using large language models. Direct competitor in AI-driven protein engineering for therapeutics.

Broad incumbents

  • Isomorphic Labs: Alphabet-owned AI drug discovery company applying DeepMind's AlphaFold to drug design. Operates at much larger scale than Galux with major pharma partnerships (Eli Lilly, Novartis) and represents the most capitalized competitor in AI protein design.
  • AbCellera Biologics: Canadian public antibody discovery platform company with established pharma partnerships. Comparable as a horizontal antibody-discovery platform, though its technology stack emphasizes high-throughput wet-lab screening rather than pure de novo AI design.
  • Insilico Medicine: Hong Kong-headquartered AI drug discovery company with Pharma.AI platform covering target discovery, generative chemistry, and clinical trial prediction. Broader scope than Galux but competing for the same AI-driven drug discovery budget pool at major pharma.

Emerging players

  • EvolutionaryScale: Early-stage AI protein foundation model company founded by former Meta AI researchers. Emerging competitor with frontier-scale models for protein design; overlap with GaluxDesign's generative AI capability.
  • Cradle Bio: Amsterdam-based AI protein engineering company with platform for designing antibodies, enzymes, and other proteins. Comparable as a generative biology platform though currently focused more on industrial biotech applications than pure therapeutics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key highlights6 records

Customer concentration

Galux social profiles

Digital presence

Galux financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Galux leadership team

Management profile

Number of profiles

Profiles6 records

Galux funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Galux M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Galux

What does Galux do?

Galux develops and operates GaluxDesign, a proprietary AI platform that integrates artificial intelligence with physics-based principles to design therapeutic proteins from scratch (de novo protein design). The platform is modality-agnostic and is delivered to pharmaceutical partners through co-development agreements, joint research collaborations, and licensing arrangements to accelerate discovery of antibody therapeutics for autoimmune diseases, cancer, and rare/incurable diseases.

Is Galux a public or private company?

Galux is a private company. It is classified as venture growth investor backed and is currently operating.

When was Galux founded?

Galux was founded in 2020. It employs 11 to 50 people.

Where is Galux based?

Galux is headquartered in Dogokdong, South Korea, in the Asia region.

How does Galux make money?

Two revenue lines are on record. Co-development and Research Partnerships are the primary driver. The others are AI Platform Licensing and Services.

Who are Galux's main competitors?

Direct peers on record are Nabla Bio, Chai Discovery, Generate Biomedicines, Iambic Therapeutics and Profluent Bio. Broad incumbents are Isomorphic Labs, AbCellera Biologics and Insilico Medicine. Emerging players are EvolutionaryScale and Cradle Bio.

Does Galux have an API?

No public API is recorded for Galux.

What industry is Galux in?

Galux's product category is AI Drug Discovery / Computational Protein Design. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening). Its NAICS code is 541714 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
WowtaleAI protein design 'Galux', new product 'Preicon' selected... securing up to 7 billion.Galux CEO Seok Cha-ok said the company's AI protein design technology was recognized in the Pre-ICON selection, emphasizing precise design for drug development. He stated the support will accelerate core technology and pipeline development to enhance global competitiveness.WowtaleNine Korean Startups Make Forbes Asia 100 to Watch 2026Nine South Korean startups were named to Forbes Asia 100 to Watch 2026, spanning AI, robotics, and beauty. Featured companies include Featuring, Wert Intelligence, and Galux, with funding totals ranging from $5 million to $74 million. The selections highlight Korea's shift toward applied technology and overseas expansion.VenturesquareDesigning proteins from scratch... Galax, Forbes Asia's 100 promising companiesGalax, a South Korean AI drug discovery company, was named one of Forbes Asia's 100 most promising companies for 2026, the only Korean biotech in the list. The company's proprietary protein design AI platform, GaluxDesign, has secured about 700 billion won in cumulative investment, and its AI-designed PD-1/IL-18v dual-antibody was selected for a national new drug program.Business Wire BlogGalux Makes the Forbes Asia 100 to Watch 2026 ListGalux, a South Korean biotechnology firm developing AI-powered protein therapeutics, was named to Forbes Asia 100 to Watch 2026, one of nine Korean companies on the list and the only in the Biotechnology & Healthcare category. Forbes cited GaluxDesign, its proprietary AI protein design platform, and partnerships with AstraZeneca and Boehringer Ingelheim, plus $47 million raised including a Series B.NateGalaxy, Park Tae-yong appointed as new CEO... Seok Cha-ok and Park Tae-yong to serve as co-CEOs: Nate NewsAI drug development company Galux has appointed Vice President Park Tae-yong as new CEO, transitioning to a dual CEO system with existing CEO Seok Cha-ok to strengthen long-term growth and prepare for an IPO targeted for end of 2027. Under the new structure, CEO Seok Cha-ok will oversee long-term vision and technology strategy while CEO Park Tae-yong will handle execution in R&D, commercialization, and organizational operations. Galux has also established a C-level management system including a CTO and CAIO, and the company has been expanding joint research partnerships with Boehringer Ingelheim, AstraZeneca, and Celltrion while its AI-designed bispecific antibody immuno-oncology drug was selected for the National Drug Development Project.WewillcureCure’s AI Drug Discovery Funding Tracker 2026Cure's funding tracker documents major AI drug discovery venture rounds of $10M or more across January through May 2026, with no new $10M+ rounds confirmed for June 2026. Isomorphic Labs raised the largest round at $2.1B Series B (bringing total funding to roughly $2.7B), making it the second-largest biotech fundraising in history after Altos Labs' $5.5B combined investment; the company is headquartered in London with a second location in Lausanne, Switzerland, and was founded by Demis Hassabis as an Alphabet-founded firm. The sector saw diverse funding activity spanning seed through Series B rounds for companies developing AI platforms spanning end-to-end drug discovery, protein design, biologics development, and molecular generation, with notable raises including Earendil Labs ($787M), Fathom Therapeutics ($47M Series A), Alloy Therapeutics ($40M Series E at $1B valuation), Galux ($29M Series B), VantAI/Proxima ($80M seed), and Generate (€20M/$23M Series A).AsiaeGalux's AI-Designed Bispecific Antibody Immunotherapy Selected for National New Drug Development ProjectGalux, an AI drug development company, announced on June 24 that its bispecific antibody immunotherapy (PD-1/IL-18v), designed using its proprietary AI protein engineering platform GaluxDesign, has been selected as a candidate substance project for Korea's National New Drug Development Project. The selection, evaluated by new drug development experts, validates the technological potential and commercial viability of an AI-designed innovative drug candidate aimed at cancer patients who do not respond to existing immunotherapies. Galux plans to advance the bispecific antibody candidate from design stage to preclinical validation through this inter-ministerial national R&D initiative.ChosunbizAstraZeneca partners with South Korea's Ezcuris and Galux on immunology and AIAstraZeneca has partnered with South Korean biotech companies Ezcuris and Galux through Project NOVA, an open innovation program co-run by the Korea Health Industry Development Institute (KHIDI) and Korea AstraZeneca, with the partnerships announced at BioUSA 2026 in San Diego. The collaborations align with AstraZeneca's stated priorities in immune diseases (including autoimmune conditions like SLE and rheumatoid arthritis) and AI-based drug development. Ezcuris is developing SIK inhibitors for immune diseases and is pursuing a Series B round valued at approximately 65 billion won, while Galux has raised about 42 billion won in Series B funding and is preparing for an IPO.KBRGalux, AimedBio partner to develop BBB-crossing protein delivery platformGalux has signed an investment and joint research agreement with AimedBio to develop a blood-brain barrier-crossing protein delivery platform that combines AI-based protein design with antibody drug development. The partnership aims to address a major technical hurdle in brain disease treatment by enabling antibody and protein therapeutics to reach brain tissue. The collaboration brings together Galux's AI protein design platform GaluxDesign and AimedBio's expanding ADC development capabilities.Business Wire BlogGalux Shows Broadest Target Coverage in Comparative De Novo Antibody Design StudyGalux, a South Korean biotechnology company, announced comparative research results showing its AI protein design platform, GaluxDesign, achieved the broadest target coverage across nine publicly comparable de novo antibody design targets, identifying experimentally validated binders for eight of the nine targets. The platform outperformed competing platforms JAM-2 by Nabla Bio (five targets) and Chai-2 by Chai Discovery (four targets) in terms of validated binder coverage. The company stated this performance demonstrates the platform's strong and consistent binder generation capability across diverse antibody design problems, potentially accelerating downstream therapeutic optimization and drug development.